You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 5,972,919


✉ Email this page to a colleague

« Back to Dashboard


Title: Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
Abstract:Effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.
Inventor(s): Carling; Christer Carl Gustav (Dalby, SE), Trofast; Jan William (Lund, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Filing Date:Oct 07, 1997
Application Number:08/944,683
Claims:1. A medicament containing as active ingredients effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1:70.

2. A pharmaceutical composition which comprises effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1:70, together with a pharmaceutically acceptable carrier.

3. A method for the treatment of asthma and other inflammatory respiratory disorders which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1.70.

4. The method according to claim 3, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 .mu.g per day, and the effective amount of budesonide is 50-4800 .mu.g per day.

5. The method according to claim 4 wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-48 .mu.g per day, and the effective amount of budesonide is 100-1600 .mu.g per day.

6. The medicament of claim 1 wherein the active ingredients are in dry powder form.

7. The medicament of claim 1 or 6 wherein the formoterol is in the form of the fumarate dihydrate.

8. The pharmaceutical composition of claim 2 wherein the formoterol is in the form of the fumarate dihydrate.

9. The method according to any one of claims 3-5 wherein the administration is performed from a dry powder inhaler.

10. The method according to claim 9 wherein the inhaler is a Turbuhaler.RTM..

11. The method according to any one of claims 3-5 wherein the administration is performed from a metered dose inhaler.

12. The method according to any one of claims 3-5 wherein the formoterol is in the form of the fumarate dihydrate.

13. A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable carrier is lactose.

14. A pharmaceutical composition according to claim 13 in dosage unit form.

15. The method according to any one of claims 3-5 wherein the administration is performed with a nebulizer.

16. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered simultaneously.

17. The method according to any one of claims 3-5 wherein the formoterol component is administered in admixture with the budesonide component.

18. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered sequentially.

19. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered separately.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.